Twist Bioscience Co. (NASDAQ:TWST) CFO Sells $254,628.36 in Stock

Twist Bioscience Co. (NASDAQ:TWST) CFO Adam Laponis sold 5,886 shares of the firm’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $43.26, for a total value of $254,628.36. Following the transaction, the chief financial officer now owns 110,096 shares in the company, valued at approximately $4,762,752.96. This trade represents a 5.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Adam Laponis also recently made the following trade(s):

• On Wednesday, November 6th, Adam Laponis sold 4,160 shares of Twist Bioscience stock. The shares were sold at an average price of $44.60, for a total transaction of $185,536.00.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $45.87 on Friday. The stock’s fifty day moving average price is $46.43 and its two-hundred day moving average price is $46.32. The firm has a market cap of $2.72 billion, a PE ratio of -12.74 and a beta of 1.85. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90.

Analyst Ratings Changes

Several equities research analysts have commented on TWST shares. TD Cowen reaffirmed a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. Leerink Partners upped their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. Robert W. Baird lifted their target price on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a report on Tuesday, November 19th. Wolfe Research began coverage on Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target for the company. Finally, Evercore ISI lifted their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $51.90.

Institutional Investors Weigh In On Twist Bioscience

A number of hedge funds have recently made changes to their positions in TWST. Massachusetts Financial Services Co. MA boosted its stake in shares of Twist Bioscience by 215.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock valued at $1,324,000 after purchasing an additional 20,035 shares in the last quarter. Barclays PLC boosted its position in Twist Bioscience by 214.8% during the 3rd quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after buying an additional 104,420 shares during the period. FMR LLC grew its holdings in Twist Bioscience by 6.0% during the 3rd quarter. FMR LLC now owns 218,561 shares of the company’s stock worth $9,875,000 after acquiring an additional 12,327 shares during the last quarter. BNP Paribas Financial Markets increased its position in Twist Bioscience by 128.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock valued at $1,718,000 after acquiring an additional 21,357 shares during the period. Finally, Principal Financial Group Inc. raised its stake in shares of Twist Bioscience by 67.5% during the third quarter. Principal Financial Group Inc. now owns 205,864 shares of the company’s stock valued at $9,301,000 after acquiring an additional 82,953 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.